Aptose Biosciences Files 8-K on Financials
Ticker: APTOF · Form: 8-K · Filed: Nov 13, 2025 · CIK: 882361
Sentiment: neutral
Topics: financial-condition, exhibits, filing
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Nov 13, 2025, covering financials and exhibits.
AI Summary
Aptose Biosciences Inc. filed an 8-K report on November 13, 2025, to disclose information regarding its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in A6 and has its fiscal year end on December 31.
Why It Matters
This filing provides investors with crucial updates on Aptose Biosciences' financial health and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate operational or financial distress.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- November 13, 2025 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- 0000882361 (company_id) — Central Index Key
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Aptose Biosciences Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.
On what date was this 8-K report filed or effective?
The report was filed as of November 13, 2025, and the date of the earliest event reported is also November 13, 2025.
What were Aptose Biosciences Inc.'s previous names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
What is Aptose Biosciences Inc.'s fiscal year end?
Aptose Biosciences Inc.'s fiscal year ends on December 31.
What is the SIC code for Aptose Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-11-13 17:00:30
Filing Documents
- f8k_111325.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 50KB
- 0001171843-25-007293.txt ( ) — 263KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_111325_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 13, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 13, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer